An observational study in Respiratory Infection, COVID-19 Respiratory Infection and Sequelae of; Infection, sponsored by Bernhard Nocht Institute for Tropical Medicine. Status unknown. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Bernhard Nocht Institute for Tropical Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Identifying multiorgan sequalae and complications through high quality, prospective matched controlled studies throughout the course of COVID-19 is important for the acute and long-term management of patients and for health systems' planning. Further, it is key to understand the link between acute illness and long term consequences particularly in those already living with other comorbidities such as cardiovascular diseases or cancer.
Since the clinical presentation of COVID-19 can resemble a variety of common respiratory infections, describing the distribution of pathogens and the severity of clinical presentation associated with COVID-like illnesses (CLI) infections is important to generate a baseline clinical description by comparing potential long-term effects of PCR-confirmed COVID-19 to those following other respiratory infections.
To gain a better understanding of the clinical burden on COVID-19 survivors we will undertake a comparative evaluation within a cohort of PCR-confirmed individuals with COVID-19 vs. those PCR-confirmed symptomatic individuals with other respiratory pathogens plus healthy individuals from the community.
The results will inform strategies to prevent long term consequences; inform clinical management, interventional research, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.
This is an observational prospective matched cohort study to evaluate the post-acute consequences of the SARS-CoV-2 symptomatic infection (case-positives) while having as comparison groups (1) symptomatic controls (case-negatives) and (2) healthy controls, that are healthy individuals recruited from the same community of the cases, but not arise from the same household. After pre-screening of COVID-19 symptoms at the hospital and other satellite health centers, consenting/assenting patients of 16 years of age and above with all range of PCR-confirmed Covid-19 disease severity -from mild to severely ill hospitalized patients- will be recruited and matched to other Non-SARS-CoV-2 PCR-determined patients and to healthy community controls. Then, they will be followed up for 12 months (13 months after screening) to determine the occurrence of admissions, any outpatient encounter, symptoms (new or persistent) and concomitant use of medication after 28 days of diagnosis.
At recruitment, respiratory samples are collected for respiratory infections diagnosis. Also, blood samples are collected to generate baseline data on potential biomarkers associated to occurrence of investigated outcomes. This will include biochemistry (including inflammatory markers) and hematology as well as SARS-CoV-2 serology (IgG) which will also be taken at the end of follow up to rule out infection during the course of the follow up. Though, the serology testing won't be done along each recruitment but in batches during the study period. Clinical (symptoms and diagnosis), socioeconomic, demographic, household conditions, health seeking behavior and medical history information will be gathered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
This study's planned enrollment of 1,232 is above the median of 350 across 184 observational studies indexed under Respiratory Tract Infections.
Browse Respiratory Tract Infections studies →Bernhard Nocht Institute for Tropical Medicine is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study takes place in Assin Foso, Assin North District, Ghana. This is a semi rural area. Participants are recruited from the Saint Francis Xavier Hospital, the reference center of the region, when the seek for health services due to respiratory symptoms. Healthy controls are recruited from the communities from where cases arise.
For symptomatic patients attending to the SFXH or other satellite health centers
Inclusion Criteria
Exclusion Criteria
Antimicrobial Use Work package (A subset of hospitalized, symptomatic patients are to be recruited as control group for the Antimicrobial Use Workpackage, if they meet the inclusion criteria)
Inclusion Criteria
For healthy controls from the community
Inclusion Criteria
Exclusion Criteria
Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).
Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.
At the community.
Admissions and Outpatient encounter
Cumulated number of admissions and outpatient encounters within 13 months post PCR diagnosis
Time frame: 13 months
Persistent or new symptoms
Cumulated number of persistent/new symptoms within 13 months post PCR diagnosis
Time frame: 13 months
Medication and therapy
Cumulated therapy and use within 13 months post PCR diagnosis defined as: 1. Average weekly intake of particular medication(s) 2. Newly use of a particular medication(s)
Time frame: 13 months
Patients' symptoms outcome
Occurrence of sequalae, post-acute symptoms and long-term patients' outcomes
Time frame: 13 months
Pathogen detection
Pathogens detected by PCR respiratory panel
Time frame: 13 months
Exploratory Endpoint 1
Viral variants detection via sequencing in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.
Time frame: 13 months
Exploratory Endpoint 2
Vaccine effectiveness in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.
Time frame: 13 months
No study locations are listed for this record.
Start is estimated for Oct 2021; primary completion for Oct 2022, 12 months later.
Of 67 non-industry observational studies under Respiratory Tract Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 8 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Bernhard Nocht Institute for Tropical Medicine